Related Experiment Video
Updated: Jun 12, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
Abstract:
In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and bupropion SR 360 mg. The drug has been tested in four randomized, double-blind, placebo-controlled, phase III trials and the co-primary endpoints were met in each case. This review discusses the key development milestones and clinical trial program to date.
More Related Videos
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
Antidepressant Drugs: MAOIs and Other Agents
CNS Depressants: Alcohol and Nicotine
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Phase I Reactions: Reductive Reactions

